trial

Psychosis: Early Detection, Intervention and Prevention

NCTId NCT01597141
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 100 (actual)
Sponsored by MaineHealth
Primary completion 2014-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
100 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2003-05
Primary completion
2014-09
Eligibility
ALL · 12 Years · 35 Years

Interventions & indications

Drugs
Family-aided Assertive Community TreatmentEnhanced standard treatment

Sponsors

MaineHealthLead Sponsor
Columbia UniversityCollaborator
Harvard UniversityCollaborator
University of California Riverside at C.I. Trials, Inc.-Inland EmpireCollaborator

Investigators

1
William R. McFarlane, M.D.Principal Investigator

Sites

1 total
Portland, United States

Facts & assertions

4 sourced
Enrollment
100
Phase
NA
Primary Completion Date
2014-09
Status
COMPLETED
relationships
The graph out of here
drug
Family-aided Assertive Community Treatment
drug
Enhanced standard treatment
drug
lead_sponsor
MaineHealth
company
collaborator
Columbia University
company
Harvard University
company
indication
Prodromal Schizophrenia
indication
Psychotic Disorders
indication
Schizotypal Personality Disorder
indication
investigator
William R. McFarlane, M.D.
person